2009 Edition **Catalogue Part Drug Name Formulation Adjustment

A few days ago, the Ministry of Human Resources and Social Security issued a notice to regulate and regulate some of the drug name formulations of the “National Basic medical Insurance, Industrial Injury Insurance and Maternity Insurance Drug List”.

The notice said that in order to better guarantee the implementation of the "National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Drug List (2009 Edition)" implementation, after the collection catalog is published and reflected by all parties, and on the basis of organizational verification, the drug name is passed by the relevant department. , verification of the scope of indications, and subject to the review of experts, the name of the relevant drug formulations and other types of adjustment and specification. At the same time, the Ministry of Personnel Protection issued a list of regulatory specifications for certain drug names in the "National Basic Medical Insurance, Industrial Injury Insurance, and Fertility Insurance Drug List." In this table, a total of 8 Western medicines and 3 Chinese herbs were adjusted. Taking the remark part of α-interferon as an example, the adjustments were: leukemia, lymphoma, melanoma, renal cell carcinoma, multiple myeloma, and hepatitis C. Adjusted to: limit leukemia, lymphoma, melanoma, kidney cancer, multiple myeloma, hepatitis C, chronic active hepatitis B; hepatitis C, chronic active hepatitis B withdrawal after 6 months of continuous use is invalid, continuous use of no more than 12 month.